Forest Products

CN HEALTH TECH

China Health Tech Group Plans Non-underwritten Rights Issue

CN HEALTH TECH released FY2026 Q1 earnings on February 27 (BJT), actual revenue HKD 18.8 M, actual EPS HKD 0.0286

CN HEALTH TECH released FY2026 Semi-Annual earnings on February 27 During-Market (BJT), actual revenue HKD 37.92 M, actual EPS HKD 0.0578

CN HEALTH TECH released FY2026 Q2 earnings during market hours on February 27, BJT, with actual revenue of HKD 19.12 M and EPS of HKD 0.0291

CN HEALTH TECH to Release FY2026 Semi-Annual Earnings on February 27, 2026 (BJT)

China Health Technology Group reports 89.5% revenue growth but 88.6% net profit decline for FY2025

CN HEALTH TECH released FY2025 9 Months Earnings on September 30 (BJT), actual revenue HKD 65.62 M, actual EPS HKD 0.1788

CN HEALTH TECH released FY2025 Q4 earnings on September 30, 2025 (BJT) with actual revenue of HKD 32.34 M and EPS of HKD 0.113

CN HEALTH TECH released FY2025 Annual Earnings on September 30, 2025 (BJT), with actual revenue of HKD 97.83 M and actual EPS of HKD 0.2983

CN HEALTH TECH released FY2025 Q3 earnings on September 30 (BJT), actual revenue HKD 31.65 M, actual EPS HKD 0.1105

CN HEALTH TECH to release FY2025 earnings report on September 30, 2025, BJT

China Health Technology Proposes Share Consolidation and Adjusts Trading Unit

China Health Tech Group Enters Strategic Partnership with Heilongjiang Jianzhitan for Ganoderma and Health Products

CN HEALTH TECH released FY2025 Q1 earnings on February 28, 2025 (BJT) with actual revenue of HKD 17.24 M and EPS of HKD 0.0348

CN HEALTH TECH released FY2025 Q2 earnings on February 28 After-Market (BJT), actual revenue HKD 16.55 M, actual EPS HKD 0.0334

CN HEALTH TECH released FY2025 Semi-Annual earnings on February 28 After-Market (BJT), actual revenue HKD 33.78 M, actual EPS HKD 0.0683

CN HEALTH TECH to Release FY2025 Semi-Annual Earnings on February 28, 2025 (BJT)

CN HEALTH TECH released FY2024 9 Months earnings on September 30, 2024 (BJT), actual revenue HKD 36.15 M, actual EPS HKD 3.4772

CN HEALTH TECH released FY2024 Q3 earnings on September 30, 2024 (BJT), with actual revenue of HKD 15.49 M and EPS of HKD -0.0106

CN HEALTH TECH released FY2024 Q4 earnings on September 30 Pre-Market (BJT), actual revenue HKD 15.36 M, actual EPS HKD -0.0105

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

01069

China Health Technology Group Holding Company Limited has announced its board composition, led by Ms. Bu Xue as chairman and CEO. The structure includes key committees chaired by independent director Mr. Chau Wing Nam, emphasizing corporate governance and independent oversight. This arrangement aims to enhance transparency in decision-making and bolster investor confidence.

Tip Ranks

China Health Technology Sets Out Board and Committee Structure

China Health Technology Group Holding Company Limited received shareholder approval for a rights issue and placing agreement at an extraordinary general meeting on May 12, 2026. The resolutions were passed unanimously, indicating strong support for the company's capital-raising efforts. This approval will enhance the company's capital base and financial flexibility for future growth. Independent shareholders accounted for over 92% of the voting capital, reflecting broad alignment on the financing strategy. The company, listed in Hong Kong, focuses on health-related technologies and services.

China Health Technology Wins Shareholder Backing for Rights Issue and Placing

CN HEALTH TECH announced a proposed rights issue, issuing 205 million shares; the rights issue price is HKD 0.25, a discount of 20.63% compared to the last trading day (27th). The maximum fundraising amount is HKD 51.5 million, with a net amount of HKD 50 million intended for the acquisition of ginseng planting land and related marketing, investment in the medical beauty industry, and general working capital

AASTOCKS

CN HEALTH TECH Group offers a rights issue at a discount of 20.63%, raising a net amount of 50 million

000028

01099

512010

Sinopharm Group Co. Ltd. has proposed a final cash dividend of RMB 0.69 per share for the financial year ending December 31, 2025. The dividend is subject to shareholder approval on June 18, 2026, with an ex-dividend date of June 23 and payment scheduled for August 18, 2026. The company has outlined tax arrangements for non-resident shareholders, which will impact net dividend receipts. The latest analyst rating for Sinopharm stock (HK:1099) is a Buy, with a price target of HK$23.00.

Sinopharm Accord

SINOPHARM

SINOPHARM(CNCM LTD)

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal 800 Health Care ETF

ChinaAMC CSI All Share Health Care Devices ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng Health Care ETF(QDII)

Huaan Hang Seng Biotech ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

E Fund CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Sinopharm Proposes Final Cash Dividend of RMB 0.69 per Share for 2025

00348

000090

CN HEALTH TECH announced its interim results for the six months ending December 2025, with revenue of 34.39 million RMB, an increase of 10.5% year-on-year. It recorded a net profit of 5.25 million RMB, a growth of 5.5%, with earnings per share of 5.25 cents. No dividend was declared

CHINAHEALTHWISE

TAGEN GROUP

"Performance" CN HEALTH TECH's interim net profit is RMB 5.25 million, an increase of 5.5%, no dividend declared

09886

AFJKU

Dingdang Health Technology Group Ltd. has announced its board and committee lineup to enhance governance. Yang Wenlong is appointed as chairman and president, supported by four executive directors, one non-executive director, and three independent non-executive directors. The audit committee will be chaired by independent director Jiang Shan, while Yang leads the nomination committee and Fan Zhenhong heads the remuneration committee. This structure aims to strengthen corporate governance and boost investor confidence. Dingdang Health, listed in Hong Kong, focuses on health technology and services, with a market cap of HK$1.17B.

DINGDANG HEALTH

Health Care Select Sector SPDR

iShares US Healthcare Providers

VG Health

Aimei Health Tech - Unit

Dingdang Health Defines Board and Committee Lineup to Bolster Governance

CN HEALTH TECH announced its financial results for the fiscal year ending in June, with revenue of RMB 90.22 million, an increase of 89.5% year-on-year. It recorded a net profit of RMB 22.71 million, a decline of 88.6%, with earnings per share of 2.75 cents. No dividend was declared

"Performance" CN HEALTH TECH Group's annual net profit is 22.71 million RMB, a decline of 88.6%

CN HEALTH TECH(01069.HK)